E
Telomir Pharmaceuticals, Inc. TELO
$1.17 $0.010.86% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$1.16
Volume
51,619
Avg Vol (90D)
1,282,778
Market Cap
$39.88M
Dividend & Yield
--
52-Week Range
$1.07 - $5.40
P/E (TTM)
--
EPS (TTM)
-$0.37
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Telomir Pharmaceuticals reports cellular study results on Telomir-1
2/5/2026 - The Fly
Telomir Pharmaceuticals Highlights Preclinical Data for Telomir-1
2/5/2026 - TipRanks Financial Blog
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
2/5/2026 - ACCESS Newswire
Telomir Pharmaceuticals initiated with a Buy at Rodman & Renshaw
1/13/2026 - TipRanks Financial Blog
Telomir Pharmaceuticals initiated with bullish view at Rodman & Renshaw
1/13/2026 - The Fly
Telomir Pharmaceuticals reports results from efficacy study for Telomir-1
1/5/2026 - The Fly
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases ...
1/5/2026 - GuruFocus
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
1/5/2026 - ACCESS Newswire
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 8.9% - Time to Sell?
1/1/2026 - Ticker Report
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% - Here's What Happened
12/30/2025 - MarketBeat
Telomir Pharmaceuticals' (TELO) Lead Candidate Telomir-1 Shows Promising Safety Profile
12/18/2025 - GuruFocus
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 ...
12/18/2025 - GuruFocus
Telomir Pharmaceuticals reports results from safety studies for Telomir-1
12/18/2025 - TipRanks Financial Blog
Telomir Pharmaceuticals reports results from safety studies for Telomir-1
12/18/2025 - The Fly
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
12/18/2025 - ACCESS Newswire
Telomir Pharmaceuticals Reports Positive IND-Enabling Study Results
12/17/2025 - TipRanks Financial Blog
Telomir Pharmaceuticals announces new preclinical data on Telomir-1
11/25/2025 - The Fly
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in ...
11/25/2025 - GuruFocus
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
11/25/2025 - ACCESS Newswire
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
11/21/2025 - GuruFocus
Telomir Pharmaceuticals (TELO) Shows Promising Results Against Leukemia Cells
11/21/2025 - GuruFocus
Telomir Pharmaceuticals announces in vitro data on Telomir-1
11/21/2025 - TipRanks Financial Blog
Telomir Pharmaceuticals announces in vitro data on Telomir-1
11/21/2025 - The Fly
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
11/21/2025 - ACCESS Newswire
Telomir Pharmaceuticals' Telomir-1 Shows Leukemia Efficacy
11/20/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$11.31M
Net Income (TTM)
-$11.25M
Balance Sheet
Total Assets (Q)
$7.40M
Total Debt (Q)
$93.40K
Total Liabilities (Q)
$422.80K
Book Value Per Share (Q)
$0.2063
Cash Flow
Cash from Operations (TTM)
-$3.09M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$9.59M
Net Change in Cash (TTM)
$6.49M
Filings
Filing Date
Monday, November 10, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 2 and 6 (est)
Price History
Loading...
Beta
0.57
7-Day Total Return
2.63%
30-Day Total Return
-19.86%
60-Day Total Return
-13.33%
90-Day Total Return
-15.83%
Year to Date Total Return
-12.69%
1-Year Total Return
-73.83%
2-Year Total Return
-81.28%
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Feb 05, 2026 - $1.07
52-week High
Mar 13, 2025 - $5.40
Valuation
Market Cap
$39.88M - Nano Cap
Enterprise Value
$32.65M
Price/Sales (TTM)
--
Price/Book (Q)
5.62
Dividends and Shares
Shares Outstanding
32.40M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
telomirpharma.com
Phone Number
786 396 6723
Address
100 SE 2nd Street
Miami, FL 33131
Country
United States
Year Founded
2021
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal... more
NASDAQ 02/10/2026 4:00PM Eastern Quotes delayed